Ondansetron

Cleft lip with or without cleft palate

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S2757
R3952		 Zambelli-Weiner (Unexposed control, NOS), 2019 Cleft lip with or without cleft palate 1st trimester nested case control unexposed (general population or NOS) Adjustment: Yes 1.69 [0.84;3.40] 8/886   696/113,802 704 886
ref
S2853
R3964		 Parker, BDS study, 2018 Cleft lip with or without cleft palate 1st trimester case control unexposed, sick Adjustment: Yes 0.80 [0.50;1.20] 27/402   450/5,948 477 402
ref
S2756
R3679		 Parker, NBDPS study, 2018 Cleft lip with or without cleft palate 1st trimester case control unexposed, sick Adjustment: Yes 1.10 [0.80;1.50] 56/268   772/3,827 828 268
ref
S2747
R3642		 Anderka, 2012 Cleft lip with or without cleft palate 1st trimester case control unexposed, sick Adjustment: Yes 0.88 [0.38;2.00] 7/51   926/4,891 933 51
ref
Total 4 studies 1.04 [0.80;1.35] 2,942 1,607
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Zambelli-Weiner (Unexposed control, NOS), 2019Zambelli-Weiner, 2019 1 1.69[0.84; 3.40]70488613%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Parker, BDS study, 2018Parker, BDS study, 2018 0.80[0.50; 1.20]47740229%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Parker, NBDPS study, 2018Parker, NBDPS study, 2018 1.10[0.80; 1.50]82826848%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Anderka, 2012Anderka, 2012 0.88[0.38; 2.00]933519%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (4 studies) I2 = 15% 1.04[0.80; 1.35]2,9421,6070.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Unexposed control, NOS;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0 case control studiescase control studies 1.04[0.80; 1.35]2,9421,60715%NAZambelli-Weiner (Unexposed control, NOS), 2019 Parker, BDS study, 2018 Parker, NBDPS study, 2018 Anderka, 2012 4 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.69[0.84; 3.40]704886 -NAZambelli-Weiner (Unexposed control, NOS), 2019 1 unexposed, sickunexposed, sick 0.98[0.77; 1.25]2,2387210%NAParker, BDS study, 2018 Parker, NBDPS study, 2018 Anderka, 2012 3 Tags Adjustment   - Yes  - Yes 1.04[0.80; 1.35]2,9421,60715%NAZambelli-Weiner (Unexposed control, NOS), 2019 Parker, BDS study, 2018 Parker, NBDPS study, 2018 Anderka, 2012 4 All studiesAll studies 1.04[0.80; 1.35]2,9421,60715%NAZambelli-Weiner (Unexposed control, NOS), 2019 Parker, BDS study, 2018 Parker, NBDPS study, 2018 Anderka, 2012 40.25.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-1.01.00.5080.000Zambelli-Weiner (Unexposed control, NOS), 2019Parker, BDS study, 2018Parker, NBDPS study, 2018Anderka, 2012

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.07[0.87; 1.32]2,34791,5170%NAZambelli-Weiner (Unexposed control, NOS), 2019 Huybrechts (Unexposed control), 2018 Fejzo (Unexposed control, disease free), 2016 Pasternak, 2013 4 unexposed, sick controlsunexposed, sick controls 0.98[0.77; 1.25]2,2387210%NAParker, BDS study, 2018 Parker, NBDPS study, 2018 Anderka, 2012 3 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.93[0.68; 1.27]23156,5310%NAHuybrechts (Control exposed to other treatment), 2018 Fejzo (Mainly exposed to other treatements, sick), 2016 20.510.01.0